Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A clinical and genetic study of SPG31 in Japan


SPG31 is an autosomal dominant hereditary spastic paraplegia caused by pathogenic variants in the receptor expression-enhancing protein 1 (REEP1) gene. We analyzed 488 DNA samples from unrelated HSP patients collected by Japan Spastic Paraplegia Research Consortium and found 15 Japanese SPG31 families. We investigated each family and found a total of 25 individuals with REEP1 variants (comprising 22 patients and three asymptomatic carriers). Fourteen REEP1 variants (five missense, three nonsense, four frameshift, one splice site, and one large deletion) including 11 novel ones were detected. Seventy percent of the patients (14 of 20) showed a pure form and the others (6 of 20) showed a complicated form with peripheral neuropathy. Fifty percent of the patients had neurological symptoms before the age of 10 and 20% of them at age 41–50. The mean age of onset was 19.6 ± 18.7 (from 5 to 67, n = 15) years for males and 32.8 ± 24.7 (from 4 to 60, n = 5) years for females. Although the difference was not statistically significant (p = 0.38, Mann–Whitney U test), males tended to have an earlier age of onset. Moreover, all three asymptomatic carriers were female. We investigated additional factors as to phenotypic appearance in one family with apparent intrafamilial variability in age at onset and clinical severity, but no additional factors including gene variants could be found. This is the first report of clinical and genetic findings of SPG31 in Japan, which may lead to further studies of the genotype–phenotype correlation of SPG31.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. Zuchner S, Wang G, Tran-Viet K-N, Nance MA, Gaskell PC, Vance JM, et al. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am J Hum Genet. 2006;79:365–9.

    Article  CAS  Google Scholar 

  2. Toft A, Birk S, Ballegaard M, Dunø M, Hjermind LE, Nielsen JE, et al. Peripheral neuropathy in hereditary spastic paraplegia caused by REEP1 variants. J Neurol. 2019;266:735–44.

    Article  CAS  Google Scholar 

  3. Beetz C, Schule R, Deconinck T, Tran-Viet K-N, Zhu H, Kremer BPH, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain. 2008;131:1078–86.

    Article  Google Scholar 

  4. Schlang KJ, Arning L, Epplen JT, Stemmler S. Autosomal dominant hereditary spastic paraplegia: novel mutations in the REEP1 gene (SPG31). BMC Med Genet. 2008;9:71.

    Article  Google Scholar 

  5. Goizet C, Depienne C, Benard G, Boukhris A, Mundwiller E, Sole G, et al. REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. Hum Mutat. 2011;32:1118–27.

    Article  CAS  Google Scholar 

  6. Hewamadduma C, McDermott C, Kirby J, Grierson A, Panayi M, Dalton A, et al. New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP). Neurogenetics. 2009;10:105–10.

    Article  CAS  Google Scholar 

  7. Du J, Shen L, Zhao GH, Wang YG, Liao SS, Chen C, et al. Receptor expression-enhancing protein 1 gene (SPG31) mutations are rare in Chinese Han patients with hereditary spastic paraplegia. Chin Med J (Engl). 2009;122:2064–6.

    CAS  Google Scholar 

  8. Kim T-H, Lee J-H, Park Y-E, Shin J-H, Nam T-S, Kim H-S, et al. Mutation analysis of SPAST, ATL1, and REEP1 in Korean patients with hereditary spastic paraplegia. J Clin Neurol. 2014;10:257–61.

    Article  Google Scholar 

  9. Ishiura H, Takahashi Y, Hayashi T, Saito K, Furuya H, Watanabe M, et al. Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses. J Hum Genet. 2014;59:163–72.

    Article  Google Scholar 

  10. Koh K, Ishiura H, Tsuji S, Takiyama Y. JASPAC: Japan Spastic Paraplegia Research Consortium. Brain Sci. 2018;8:153.

    Article  Google Scholar 

  11. Park HJ, Lee MJ, Lee JE, Park KD, Choi Y-C. Pathogenic variant of REEP1 in a Korean family with autosomal-dominant hereditary spastic paraplegia. J Clin Neurol. 2018;14:248–50.

    Article  Google Scholar 

  12. Kamada M, Kawarai T, Miyamoto R, Kawakita R, Tojima Y, Montecchiani C, et al. Spastic paraplegia type 31: a novel REEP1 splice site donor variant and expansion of the phenotype variability. Parkinsonism Relat Disord. 2018;46:79–83.

    Article  Google Scholar 

  13. Richard S, Lavie J, Banneau G, Voirand N, Lavandier K, Debouverie M. Hereditary spastic paraplegia due to a novel mutation of the REEP1 gene: case report and literature review. Medicine (Baltimore). 2017;96:e5911.

    Article  CAS  Google Scholar 

  14. Beetz C, Pieber TR, Hertel N, Schabhuttl M, Fischer C, Trajanoski S, et al. Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V. Am J Hum Genet. 2012;91:139–45.

    Article  CAS  Google Scholar 

  15. Parodi L, Fenu S, Barbier M, Banneau G, Duyckaerts C, Tezenas du Montcel S, et al. Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex. Brain. 2018;141:3331–42.

    Article  Google Scholar 

  16. Proukakis C, Moore D, Labrum R, Wood NW, Houlden H. Detection of novel mutations and review of published data suggests that hereditary spastic paraplegia caused by spastin (SPAST) mutations is found more often in males. J Neurol Sci. 2011;306:62–65.

    Article  CAS  Google Scholar 

  17. Orlacchio A, Kawarai T, Gaudiello F, Totaro A, Schillaci O, Stefani A, et al. Clinical and genetic study of a large SPG4 Italian family. Mov Disord. 2005;20:1055–9.

    Article  Google Scholar 

  18. Mitne-Neto M, Kok F, Beetz C, Pessoa A, Bueno C, Graciani Z, et al. A multi-exonic SPG4 duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree. Eur J Hum Genet. 2007;15:1276–9.

    Article  CAS  Google Scholar 

  19. Simpkins JW, Singh M. More than a decade of estrogen neuroprotection. Alzheimers Dement. 2008;4:S131–S136.

    Article  CAS  Google Scholar 

  20. Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, et al. Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res. 2004;14(Suppl A):S18–33.

    Article  CAS  Google Scholar 

  21. Park SH, Zhu PP, Parker RL, Blackstone C. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. J Clin Invest. 2010;120:1097–110.

    Article  CAS  Google Scholar 

  22. Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126:307–28.

    Article  CAS  Google Scholar 

Download references


We thank all the participants and cooperating doctors in the Japan Spastic Paraplegia Research Consortium. The following programs provided financial support to the conduct of this research, including the study design, collection, analysis and interpretation of data, and writing of the manuscript: Grants-in-Aid from the Research Committee for Ataxic Disease (YT) the Ministry of Health, Labor and Welfare, Japan, and JSPS KAKENHI Grant Numbers 19K16910 (KK) and JP21K07456 (YT) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

Author information

Authors and Affiliations



TH and YT designed and organized the study. TH acquired the clinical and laboratory data. TH, HN, KK and HI carried out the molecular genetic studies, and TH, ST and YT analyzed the molecular and clinical data. TH wrote the manuscript, which was edited by HI, ST and YT. All authors have read and approved the final version of the manuscript submitted by YT.

Corresponding author

Correspondence to Yoshihisa Takiyama.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hata, T., Nan, H., Koh, K. et al. A clinical and genetic study of SPG31 in Japan. J Hum Genet 67, 421–425 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links